Please login to the form below
National Cancer Institute
This page shows the latest National Cancer Institute news and features for those working in and with pharma, biotech and healthcare.
AZ’s comeback drug cediranib stumbles in phase 3 trial
The National Cancer Institute-sponsored GY004 study compared cediranib plus AZ and Merck &Co/MSD's leading PARP inhibitor Lynparza (olaparib) against chemo in patients with platinum-sensitive ovarian cancer, but ... and cervical cancer indications,
Latest news
-
Merck chases Roche with triple-negative breast cancer data for Keytruda
TNBC is an aggressive and hard-to-treat subtype of breast cancer, representing around 15% of all breast cancer worldwide, approximately 300, 000 cases every year. ... KEYNOTE-242 is a National Cancer Institute (NCI) sponsored trial testing adjuvant use
-
UPDATED: Senate officially confirms Stephen Hahn as FDA commissioner
Interim acting FDA commissioner Ned Sharpless returned to his role as the director of the National Cancer Institute, after completing his tenure at the federal agency on 1 November. ... This includes the Friends of Cancer research, as well as the
-
MD Anderson exec Stephen Hahn to be nominated FDA commissioner
Current acting FDA commissioner Ned Sharpless (pictured below, right) is set to return to his role as the director of the National Cancer Institute, after completing his tenure at the federal ... He oversaw the largest layoffs in its history but ensured
-
FDA will maintain the pace, vows Woodcock, but warns of skills gap
His successor, Ned Sharpless has been drafted in from his former role as head of the National Cancer Institute (NCI), but remains for now an interim Commissioner, and one certainly less
-
Iovance up on good ASCO abstract data for cervical cancer therapy
big gainer was Iovance Biotherapeutics which climbed on data for its cancer immunotherapies. ... Iovance’s approach to immunotherapy was pioneered by Steven Rosenberg of the US National Cancer Institute (NCI).
Merck chases Roche with triple-negative breast cancer data for Keytruda
UPDATED: Senate officially confirms Stephen Hahn as FDA commissioner
MD Anderson exec Stephen Hahn to be nominated FDA commissioner
FDA will maintain the pace, vows Woodcock, but warns of skills gap
Iovance up on good ASCO abstract data for cervical cancer therapy
More from news
Approximately 1 fully matching, plus 88 partially matching documents found.
Latest Intelligence
-
Guiding star of science leads AstraZeneca to breakthrough in child tumour therapy
Selumetinib was given ‘breakthrough therapy’ status and rapidly green-lit by the FDA last month (April) following a promising National Cancer Institute (NCI) Cancer Therapy Evaluation Program sponsored phase 2 trial. ... I’ve been working on
-
20 for 2020 – Five pharma leaders to watch in 2020
and Braftovi) that Pfizer thinks could become a top industry franchise in colorectal cancer when combined with antibody drug cetuximab. ... as director of the National Cancer Institute.
-
30 Women Leaders in UK Healthcare (part 3)
As Director of the MRC Clinical Trials Unit she has led the National Cancer Research Network in applying clinical trials for the improvement of cancer management in the UK. ... She now sits in the House of Lords as an independent peer, and is chair of
-
An effective commercial model for cancer care
Treatments for cancer are among the most expensive of all, regardless of disease. ... In an online survey of 8, 411 cancer patients administered by LIVESTRONG (the Lance Armstrong Foundation) and the National Cancer Institute's Health Information
-
EATRIS and the new age of partnering
In a display of its global ambition, EATRIS is joining with Cancer Research UK to bring representatives of the US's National Cancer Institute to a workshop in Brussels in October ... In October the National Cancer Institute will meet with specialists -
Guiding star of science leads AstraZeneca to breakthrough in child tumour therapy
20 for 2020 – Five pharma leaders to watch in 2020
30 Women Leaders in UK Healthcare (part 3)
An effective commercial model for cancer care
EATRIS and the new age of partnering
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest appointments
-
McCann Health France strengthens team with two new hires
Prior to McCann Health France, she served as scientific director at various international health organisations, including the ARC Foundation for Cancer Research and the French National Cancer Institute.
-
Cancer Research UK's Karen Vousden to join BMS board
She has more than 30 years experience in cancer research and her previous roles have included director of the Beatson Institute for Cancer Research and leadership positions at the US National ... Cancer Institute.
-
AZ and Medimmune bolsters immuno-oncology leadership
roles at the National Cancer Institute (NCI). ... Institut Gustave Roussy - a leading cancer-research institute.
-
Iris Pauporté joins OSE Immunotherapeutics
Pauporté will lead the clinical development of the firm's lung cancer candidate Tedopi, which is currently in phase III trials, and will be responsible for exploring the drug's potential ... She brings over 20 years of biomedical and clinical research
-
AstraZeneca appoints Sean Bohen as chief medical officer
Before joining Genentech he was a clinical instructor in oncology at Stanford University School of Medicine, a research associate at the Howard Hughes Medical Institute and a postdoctoral fellow at the ... National Cancer Institute.
McCann Health France strengthens team with two new hires
Cancer Research UK's Karen Vousden to join BMS board
Iris Pauporté joins OSE Immunotherapeutics
AstraZeneca appoints Sean Bohen as chief medical officer
More from appointments
Approximately 0 fully matching, plus 9 partially matching documents found.
Latest from PMHub
-
September 2020: diversity and inclusion in clinical trials round-up
population. There is the same problem in Europe.” Luis E. Raez, MD, of Memorial Cancer Institute/Florida International University in Miami, one of the co-authors. ... According to data from the National Cancer Institute, cancer death rates have been
-
Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)
References. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer stat facts: Liver and intrahepatic bile duct cancer. ... 2018; 15(10):599-616. National Cancer Institute. Surveillance, Epidemiology, and End Results
-
World AIDS Day 2018: Fighting the stigma surrounding HIV
HIV infection. Nat Rev Dis Primers. 2015; 1: 15035. National Cancer Institute. ... HIV infection and cancer risk. Available at: . Accessed November 2018. UCSF Health. AIDS diagnosis. Available at: . Accessed November 2018. Avert. Symptoms and stages of
-
Mastering the precision medicine opportunity
The National Cancer Institute and the Centre for Disease Control both use the 4Ps model to define precision medicine, considering it a form of evidence-based medicine that is:. ... Parallel to the increasing number of testing options is the evolving
-
ASCO 2015: What you missed in Chicago
Specifically, we thought the checkpoint inhibitors in head and neck, lung cancer and melanoma really shone. ... The second area that really impressed me was the large National Cancer Institute (NCI) trial[3] that will look to treat patients with solid
September 2020: diversity and inclusion in clinical trials round-up
More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account Director, Publications, Opthalmology, Medical Com...
-
Highly competitive salary
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
-
Senior Account Manager
-
Salary TBC
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
- Group Account Director, Patient Engagement & Solutions, Lond...
-
Highly competitive salary
- Client Services Director, Patient Engagement & Solutions, Lo...
-
Highly competitive salary
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
-
Planner
-
Salary TBC
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
- Account Director, Publications, Opthalmology, Medical Communicat...
-
Highly competitive salary
- Senior Account Director, Publications, Women’s health, Medical C...
-
Highly competitive salary
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
- Senior Medical Writer, Rare diseases, Medical Communications age...
-
Highly competitive salary
- Pfizer/BioNTech, AZ vaccines effective against Delta COVID-19 variant after two doses
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Court rules on AZ and EU’s COVID-19 vaccine dispute
- BMS and Eisai to collaborate in deal worth up to $3.1bn
- BMS’s oral AML therapy Onureg receives EU approval
- Disappointing results from CureVac’s COVID-19 vaccine as phase 2/3 study shows only 47% efficacy
- Breaking Down the Wall: Blockchain in Healthcare and Pharma
- Building Better Patient Advocates Through Authentic Partnerships
- Virgo Health makes two hires to leadership team
- Hanover Health appoints Aleksandra Lugović as an associate director
- GSK aims for £33bn in sales by 2031 as CEO Walmsley lays out ten-year strategy
- Biogen plans confirmatory trial as FDA documents show struggle over Aduhelm approval
- Biogen discontinues clinical development of anti-tau antibody for Alzheimer’s disease
- Pfizer/BioNTech, AZ vaccines effective against Delta COVID-19 variant after two doses
- BMS and Eisai to collaborate in deal worth up to $3.1bn
- Diversity and inclusion in clinical trials
- BMS’ CAR T therapy Breyanzi shows benefit in B-cell lymphoma study
- Disappointing results from CureVac’s COVID-19 vaccine as phase 2/3 study shows only 47% efficacy
PMHub
Dovetail
We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...
Latest intelligence
- Numbers, navigation, and narratives: digital storytelling in medical communications
- Science and storytelling aren’t often seen as compatible. One is based on cold, hard facts, while the other is synonymous with improvisation and theater. However, when done well, storytelling can...
- Is this common data mistake killing your digital patient recruitment?
- Without realising, you could be falling into the trap of using social data — insights into recent, relevant trends and topics — to inspire your content. Hold up. That sounds...
- The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
- By Henry Skinner, Chief Executive Officer of the AMR Action Fund...
